140,125 Shares in Certara, Inc. $CERT Bought by Tejara Capital Ltd

Tejara Capital Ltd acquired a new position in shares of Certara, Inc. (NASDAQ:CERT) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 140,125 shares of the company’s stock, valued at approximately $1,639,000.

Other large investors have also recently bought and sold shares of the company. Teacher Retirement System of Texas increased its holdings in Certara by 25.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after buying an additional 1,145,554 shares during the period. Select Equity Group L.P. boosted its position in shares of Certara by 534.5% during the 1st quarter. Select Equity Group L.P. now owns 1,094,495 shares of the company’s stock worth $10,836,000 after acquiring an additional 922,007 shares in the last quarter. Pier Capital LLC bought a new position in Certara in the second quarter valued at approximately $7,809,000. Ameriprise Financial Inc. raised its position in Certara by 13.6% during the first quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock valued at $42,526,000 after purchasing an additional 515,911 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Certara during the first quarter worth $4,950,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CERT has been the topic of several recent analyst reports. Barclays decreased their price target on Certara from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Craig Hallum initiated coverage on Certara in a research report on Monday, September 29th. They issued a “buy” rating and a $16.00 target price on the stock. UBS Group dropped their target price on shares of Certara from $17.50 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Rothschild & Co Redburn initiated coverage on shares of Certara in a report on Friday, November 21st. They set a “buy” rating and a $10.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Certara in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $13.82.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $10.92, for a total value of $559,366.08. Following the sale, the insider owned 73,979 shares of the company’s stock, valued at $807,850.68. The trade was a 40.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.33% of the company’s stock.

Certara Stock Performance

Certara stock opened at $9.14 on Friday. The business has a 50 day moving average of $11.10 and a 200-day moving average of $11.06. The company has a market capitalization of $1.46 billion, a P/E ratio of 130.57 and a beta of 1.44. Certara, Inc. has a 1 year low of $8.02 and a 1 year high of $15.69. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.09 and a quick ratio of 2.09.

Certara (NASDAQ:CERT) last posted its earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The business had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. During the same period last year, the company earned $0.13 EPS. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.